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| INTRODUCTION
The development of venous thromboembolism is multifactorial and results from environmental risk factors and patient characteristics that can be acquired, inherited, or unknown. Left iliac venous compression syndrome (IVCS), also known as May-Thurner Syndrome (MTS), which denotes compression of the left common iliac vein by the right common iliac artery, can cause unilateral lower extremity swelling, discomfort, and is thought to be a risk factor for thrombosis. 1 There are no standard diagnostic criteria for MTS diagnosis by imaging 2 ; the degree of measured venous compression may depend on more than one factor, including an individual's volume status. 3 Diagnosis requires persistent narrowing of the left iliac vein regardless of positioning 2 with MTS anatomy suggested by venous collateral development, hemodynamic flow >2 mmHg across the stenotic segment, or degree of left common iliac vein stenosis (e.g, >50% reduction in the luminal venous diameter). 2 The prevalence of MTS is currently unknown with a spectrum of estimates. Autopsy assessments have identified a left iliac "spur," caused by left iliac vein compression by the right iliac artery, in 14%-22% of cadavers. 1, 4 One study of 77 patients presenting with left lower extremity symptoms, found that nearly 50% had evidence of iliac vein compression. 5 Another study screened 50 patients with abdominal complaints but without lower extremity symptoms utilizing computed tomographic scans; 25% of the individuals had hemodynamically significant lesions causing at least 50% stenosis in the left common iliac vein while 66% had at least 25% compression. 6 The lack of precise prevalence rates for MTS in the general population and among those with lower extremity symptoms makes it difficult to evaluate the clinical significance of iliac vein compression.
Management of acute thrombosis in the setting of MTS has evolved over the past two decades with the use of endovascular management, angioplasty, and stent placement to address the acute thrombus and vascular stenosis. 7, 8 Compared to anticoagulation alone, endovascular angioplasty and stent placement may decrease the risk of recurrent thrombosis and/or severe post-thrombotic syndrome, 5 but its benefits are not well established. This is not a review of the evidence evaluating the impact of endovascular stent placement itself. Rather, this review summarizes the available evidence to support choice of drug, dose, and duration of antithrombotic therapy after stent placement for patients with left IVCS and acute thrombosis.
| MATERIALS AND METHODS
We performed a systematic review of the literature to examine the utilization of anticoagulants in the setting of venous stent placement for acute deep venous thrombosis associated MTS. A search of PubMed from inception until December 15, 2017 was undertaken regarding terms "left iliac venous" or "left iliac vein" or "May-Thurner syndrome" or "May-Thurner Syndrome" and "Stents" or "stent" and English language. A search of Embase was undertaken regarding terms "May-Thurner or "lower extremity deep vein thrombosis" or "left iliac venous" or "left iliac vein" and "stent" and English language. A search of Scopus was undertaken regarding terms "stent" and "may-thurner syndrome" or "lower extremity deep vein thrombosis" and English language. A search of Web of Science was undertaken regarding terms "lower extremity deep vein thrombosis" or "may-thurner syndrome"
| Study selection
Studies were considered potentially eligible for this systematic review if they met all of the following criteria: (a) assessed outcomes of stent patency and/or recurrent thrombosis in individuals diagnosed with an acute DVT and MTS treated with endovascular stenting; (b) followed patients for at least 12 months with stent or lower extremity imaging; (c) at least 75% of the patients were evaluated at 12 months; (d) anticoagulation was described as drug, dose, and duration; and (e) included at least three patients.
From 396 papers, five were eligible for inclusion. [9] [10] [11] [12] [13] The other 391 studies were excluded for a variety of reasons, including:
small number of patients (114), lack of outcome reporting (30), and published as abstract only (61). Figure 1 provides details about the reasons that most papers were excluded. Some articles were excluded if the title and abstract clearly did not meet all the inclusion criteria, but if there was doubt the full paper was reviewed (see Figure 1 ). 
| Data extraction

| RESULTS
The five included articles were all retrospective and describe outcomes of 61 patients with MTS and thrombosis who underwent endovascular stent placement and a subsequent antithrombotic treatment ( Table 1 ). The majority of the patients included in this review were female, which is consistent with prior reports of MTSassociated DVT (Table 2 ).
| Endovascular procedure
A variety of methods of acute thrombus management were utilized in the included studies. Of the five included articles, one utilized catheter directed thrombolysis (CDT), 13 two utilized pharmocomechanical thrombolysis (PMT), 9,10 one used either CDT or PMT, 12 and one utilized surgical thrombectomy with arterio-venous fistula formation and thrombolysis (TT) 11 as initial management of acute DVT (Table 2 ).
In-stent occlusion or thrombosis was seen in one patient treated with PMT, one patient treated with a combination of CDT + PMT, two patients treated with TT, and three patients treated with CDT alone.
| Thrombotic risk factors
Three of the five articles reported hypercoagulable testing or thrombotic risk factors. The use of thrombophilia testing (and the clinical impact of its results) was inconsistent and incompletely reported among the five studies (Table 3) . Regarding stent outcomes, patients with and without thrombophilia were found to have stent occlusion within 12 months of intervention. Two of the six patients with thrombophilia (30%), two of the 19 patients found to be negative for thrombophilia (10%), and three of the 36 with an unknown thrombophilia status (8%) experienced stent occlusion of thrombosis recurrence within 12 months of stenting. The available data do not permit any conclusions about the impact (or lack thereof) that thrombophilia testing should have on decisions about antithrombotic therapy after stent placement.
| Antithrombotic therapy
Of the five studies, four utilized warfarin as the anticoagulant for all patients studied, [9] [10] [11] 13 with goal international normalized ratio (INR) 2-3 for three studies, and 1.5-2.5 for the remaining article (Table 4) . A total of five stent occlusions or recurrent thrombosis occurred within these four studies.
The only study that utilized a spectrum of anticoagulants For the 11 patients with only 6 months of warfarin antithrombotic therapy the 12-month stent patency rate was 78% (7 of 9 evaluable at 12 months). 11 For the 50 patients treated with more than 6 months of antithrombotic therapy (variable length of systemic anticoagulation or anticoagulation followed by dual-antiplatelet therapy) the 12-month stent patency rate was 89% (41 of 46 evaluable at 12 months). For the 25 patients treated with variable anticoagulation or long-term anticoagulation without antiplatelet therapy, the 12-month a stent patency rate (17 of 21 evaluable at 12 months) was 81%.
Thus, stent thrombosis or occlusion occurred in 10%-20% of patients post-stent placement regardless of antithrombotic management, with 12.7% stent thrombosis or occlusion overall (7 of 55 evaluable at 12 months).
| Post-thrombotic syndrome
Patients were assessed for post thrombotic syndrome (PTS) in all five included studies. 
| Follow-up
As it is as least typical for patients to be anticoagulated for a minimum of 6 months after stent placement, we sought a follow-up period of at least 12 months to evaluate the risk of stent occlusion following antithrombotic discontinuation, in the cases of discontinuation. The percent of stented patients evaluable for stent occlusion or recurrent thrombosis at 12 months ranged from 77% to 100%. Of the 55 patients evaluable, the 12-month rate of endovascular stent occlusion or recurrent DVT ranged from 0% to 40%. Stent patency based on those evaluable at 12 months ranged from 60% to 100% (see Table 5 ).
| DISCUSSION
The optimal management of May-Thurner Syndrome associated thrombosis following venous stenting is not well established. We revealing stent occlusion of 65% in the thrombolysis alone group (19 of 27) and 11% in the study group (5 of 45). This study could not be utilized in our systematic review because patients were not followed for a minimum of 12 months and the duration of anticoagulation was not clearly delineated. While suggesting that endovascular stenting may provide a role in the management of some cases of MTS, the benefit of stent placement is not well established. We did not find any evidence to address pertinent questions regarding stenting such as the role for stenting in individuals without a thrombosis.
Left iliac vein compression syndrome is a nonpathologic variant in some individuals, affecting possibly 25% of the adult population, most of whom have never experienced thrombosis. 6 Population data like these suggest that the presence of IVCS is unlikely to be the sole contributor to thrombosis formation in MTS. Addressing IVCS stenosis with angioplasty or stent placement therefore may not be sufficient treatment in all patients with this anatomic anomaly. Since a foreign intravascular device can be prothrombotic, some anticoagulation therapy is almost certainly necessary, but the optimal type and duration is unclear.
This review specifically evaluated the evidence informing antithrombotic use in the post-stent setting of MTS patients with a thrombosis. The optimal duration of anticoagulation or antiplatelet therapy following stent placement is not known. 15 Our review demonstrates that 12-month stent patency rate was high, ranging from 60% to 96%, with the variety of antithrombotic management described. As these were all retrospective studies with small sample sizes, the decisions regarding specific antithrombotic therapy decisions in the review may be due to varying risks of recurrence. Thus, patients treated with longer-term anticoagulation may have been deemed to be at higher risk of recurrent thrombosis. This illustrates a need for prospective randomized studies with well-delineated baseline thrombosis risk factor assessment. In agreement with others who have published on this topic, 16 we suggest assessing patients which likely excluded studies with some information on anticoagulant use in the post-stent setting because many studies used "at least" or "a minimum of 6 months" of anticoagulation. We accepted a lower number of studies included in order to examine the outcomes of patients after the traditional 6 months of anticoagulation to compare outcomes between those who continued or discontinued anticoagulation after 6 months. Our inclusion criteria excluded some studies that did not clearly define anticoagulant dosing and duration; the goal of this review was to assess the impact of antithrombotic agents on stent outcomes.
Other studies that would not have been captured by our search strategy would include those that did not incorporate our search terms, conference proceedings, non-English language studies, papers not included in the electronic databases utilized for our 
